

Amendments to the Claims:

Claims 1-33 (Canceled)

34. (Currently amended) The transgenic mouse of claim 4543, ~~wherein where the mouse is homozygous for said null allele and the mouse is male, wherein the transgenic mouse exhibits, relative to a wild-type control mouse, at least one of reduced thymus weight, reduced thymus size, reduced thymus to body weight ratio, increased susceptibility to seizure and/or a stimulus processing deficit, and wherein where the mouse is homozygous for said null allele and the mouse is female, the transgenic mouse exhibits, relative to a wild-type control mouse, at least one of increased susceptibility to seizure and/or a stimulus processing deficit.~~
35. (Currently amended) The transgenic mouse of claim 34, wherein the increased susceptibility to seizure is characterized by a lower dose of metrazol required to reach characteristic stages of seizure, relative to a wild-type control mouse.
36. (Currently amended) The transgenic mouse of claim 34, wherein the stimulus processing deficit is characterized by a decrease in prepulse inhibition, relative to a wild-type control mouse.
37. (Currently amended) A cell or tissue isolated obtained from the transgenic mouse of claim 3443.
38. (Canceled)
39. (Canceled)
40. (Canceled)
41. (Currently amended) A method of producing thea transgenic mouse of claim 43 whose genome comprises a disruption in the endogenous mouse anaphylatoxin C3a receptor gene, the method comprising:
- (a) introducing a targeting construct capable of disrupting the endogenous mouse anaphylatoxin C3a receptor gene into a mouse embryonic stem cell;
 - (b) introducing the mouse embryonic stem cell into a blastocyst;
 - (c) implanting the blastocyst into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a chimeric mouse; and

(d) breeding the chimeric mouse to produce the transgenic mouse whose genome comprises the disruption in the endogenous mouse anaphylatoxin C3a receptor gene; wherein where the disruption is homozygous and the mouse is male, the transgenic mouse lacks production of functional anaphylatoxin C3a receptor and exhibits, relative to a wild type mouse, reduced thymus weight, reduced thymus size, reduced thymus to body weight ratio, increased susceptibility to seizure or a stimulus processing deficit, and wherein where the disruption is homozygous and the mouse is female, the transgenic mouse lacks production of functional anaphylatoxin C3a receptor and exhibits, relative to a wild type mouse, increased susceptibility to seizure or a stimulus processing deficit.

42. (Canceled)
43. (Currently amended) A transgenic mouse whose genome comprises a null endogenous anaphylatoxin C3a receptor allele, said null allele comprising exogenous DNA: said exogenous DNA comprising a gene encoding a visible marker.
44. (Previously presented) The transgenic mouse of claim 43 wherein said mouse is heterozygous for said null allele.
45. (Previously presented) The transgenic mouse of claim 43 wherein said mouse is homozygous for said null allele.
46. (Currently amended) The transgenic mouse of claim 43 wherein said null allele exogenous DNA comprises a gene encoding a selectionselectable marker.
47. (Previously amended) The transgenic mouse of claim 46 wherein said gene is a neomycin resistant gene.
48. (Currently amended) The transgenic mouse of claim 47 wherein said null allele further comprises a visible marker is lacZ gene.